Increasing Ebola transmission behaviors 6 months post-vaccination: Comparing vaccinated and unvaccinated populations near 2018 Mbandaka Ebola outbreak in the Democratic Republic of Congo.

Democratic Republic of the Congo (DRC) Ebola Post-outbreak behaviors Post-vaccination behaviors Vaccination behaviors rVSV-EBOV

Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
17 12 2021
Historique:
received: 07 05 2021
revised: 01 10 2021
accepted: 26 10 2021
pubmed: 21 11 2021
medline: 27 1 2022
entrez: 20 11 2021
Statut: ppublish

Résumé

In 2018, the Democratic Republic of the Congo (DRC) declared its 9th and 10th Zaire ebolavirus (EBOV) outbreaks, in the Equateur province (end: July 2018), and in the eastern provinces including North Kivu (end: June 2020). The DRC Ministry of Health deployed the rVSV-vectored glycoprotein (VSV-EBOV) vaccine in response during both outbreaks. A cohort of vaccinated and unvaccinated individuals from the Equateur province were enrolled and followed prospectively for 6 months. Among participants included in this analysis, 505 were vaccinated and 1,418 were unvaccinated. Differences in transmission behaviors pre- and post- outbreak were identified, along with associations between behaviors and vaccination. There was an overall increase in the proportion of both unvaccinated and vaccinated individuals in Mbandaka who participated in risky activities post-outbreak. Travel outside of the province pre-outbreak was associated with vaccination. Post-outbreak, vaccinated individuals were less likely to participate in funeral traditions than unvaccinated individuals. A net increase in activities considered high risk was observed in both groups despite significant efforts to inform the population of risky behaviors. The absence of a reduction in transmission behavior post-outbreak should be considered for improving future behavior change campaigns in order to prevent recurrent outbreaks.

Sections du résumé

BACKGROUND
In 2018, the Democratic Republic of the Congo (DRC) declared its 9th and 10th Zaire ebolavirus (EBOV) outbreaks, in the Equateur province (end: July 2018), and in the eastern provinces including North Kivu (end: June 2020). The DRC Ministry of Health deployed the rVSV-vectored glycoprotein (VSV-EBOV) vaccine in response during both outbreaks.
METHODS
A cohort of vaccinated and unvaccinated individuals from the Equateur province were enrolled and followed prospectively for 6 months. Among participants included in this analysis, 505 were vaccinated and 1,418 were unvaccinated. Differences in transmission behaviors pre- and post- outbreak were identified, along with associations between behaviors and vaccination.
RESULTS
There was an overall increase in the proportion of both unvaccinated and vaccinated individuals in Mbandaka who participated in risky activities post-outbreak. Travel outside of the province pre-outbreak was associated with vaccination. Post-outbreak, vaccinated individuals were less likely to participate in funeral traditions than unvaccinated individuals.
CONCLUSION
A net increase in activities considered high risk was observed in both groups despite significant efforts to inform the population of risky behaviors. The absence of a reduction in transmission behavior post-outbreak should be considered for improving future behavior change campaigns in order to prevent recurrent outbreaks.

Identifiants

pubmed: 34799143
pii: S0264-410X(21)01404-3
doi: 10.1016/j.vaccine.2021.10.071
pmc: PMC8687134
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

7464-7469

Subventions

Organisme : NIAID NIH HHS
ID : K23 AI146268
Pays : United States
Organisme : NIAID NIH HHS
ID : L30 AI126521
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM130900
Pays : United States

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Vaccine. 2018 Aug 28;36(36):5454-5459
pubmed: 28780120
Lancet. 2017 Feb 4;389(10068):505-518
pubmed: 28017403
N Engl J Med. 2018 Nov 22;379(21):1981-1983
pubmed: 30281389
Trends Microbiol. 2015 Feb;23(2):65-6
pubmed: 25535021
Hum Vaccin Immunother. 2016 Jun 2;12(6):1435-50
pubmed: 26864126
N Engl J Med. 2021 Apr 1;384(13):1240-1247
pubmed: 33789012
N Engl J Med. 2019 Dec 12;381(24):2293-2303
pubmed: 31774950
Lancet. 2015 Aug 29;386(9996):857-66
pubmed: 26248676

Auteurs

Nicole A Hoff (NA)

Department of Epidemiology, University of California, Los Angeles, Fielding School of Public Health, Los Angeles, CA, USA. Electronic address: nhoff84@ucla.edu.

Anna Bratcher (A)

Department of Epidemiology, University of California, Los Angeles, Fielding School of Public Health, Los Angeles, CA, USA. Electronic address: abratcher@ucla.edu.

Patrick Mukadi (P)

Institut National de Recherche Biomédicale, Kinshasa, Congo.

Steve Ahuka (S)

Institut National de Recherche Biomédicale, Kinshasa, Congo.

Michel Kabamba (M)

National Expanded Program for Immunization, Kinshasa, Congo.

Kamy Musene (K)

Institut National de Recherche Biomédicale, Kinshasa, Congo.

Megan Halbrook (M)

Department of Epidemiology, University of California, Los Angeles, Fielding School of Public Health, Los Angeles, CA, USA. Electronic address: meganhalbrook@ucla.edu.

Camille Dzogong (C)

UCLA-DRC, Kinshasa, Congo.

Guillaume Ngoie Mwamba (GN)

National Expanded Program for Immunization, Kinshasa, Congo.

Placide Mbala (P)

Institut National de Recherche Biomédicale, Kinshasa, Congo.

J Daniel Kelly (JD)

School of Medicine, University of California, San Francisco, San Francisco, CA, USA. Electronic address: dan.kelly@ucsf.edu.

Jean Paul Kompany (JP)

Institut National de Recherche Biomédicale, Kinshasa, Congo.

Merly Tambu (M)

Institut National de Recherche Biomédicale, Kinshasa, Congo.

Didine Kaba (D)

Ecole de Sante Publique, Université de Kinshasa, Kinshasa, Congo. Electronic address: didine.kaba@unikin.ac.cd.

Benoit Kebela-Ilunga (B)

Direction de lutte contre la Maladie-Ministère de la Santé Publique, Kinshasa, Congo.

Jean Jacque Muyemebe-Tamfum (JJ)

Institut National de Recherche Biomédicale, Kinshasa, Congo.

Anne W Rimoin (AW)

Department of Epidemiology, University of California, Los Angeles, Fielding School of Public Health, Los Angeles, CA, USA. Electronic address: arimoin@g.ucla.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH